Member Info for soulac

I said earlier people do not understand what they have got, it’s all most to unbelievable,

https://www.mountsinai.org/health-library/diseases-conditions/autoimmune-disorders

Addison disease

Celiac disease - sprue (gluten-sensitive enteropathy)

Dermatomyositis

Graves disease

Hashimoto thyroiditis

Inflammatory bowel disease (Crohn disease, ulcerative colitis)

Multiple sclerosis

Myasthenia gravis

Pernicious anemia

Reactive arthritis

Rheumatoid arthritis

Sjögren syndrome

Systemic lupus erythematosus (lupus)

Type I diabetes

Cancer is an autoimmune disease, boom, 10p plus tomorrow,

Then it will keep climbing

Just a thought, could they move towards AI

Why RNS this if they are not just about to sign a mega deal,

I wouldn’t be surprised if we get news tomorrow,

From the RNS 8th January

The advances made by ImmuPharma with the P140 program, particularly in the latter part of 2024, have led to significant interest from leading Biopharmaceutical companies and we are progressing discussions as we move to establish global licensing agreements.

There have been eleven $1bn+ licensing deals for immunology assets across the BioPharma industry from 2023 to late September 2024. The current trend suggests that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.

From what he said looks like it will be at least 4 deals plus,

He also said all the work they have been doing over the last three years will finally be delivered THIS Year,

And from the CEO mouth transformational year,

From tomorrow it should only be possible for the company, iMO

Morning all,

I personally think people are a bit miffed to the reaction to the recent news, This is a massive break though in medical science,

Which was announced two weeks ago and the sp hasn’t even started to reflect the true value of this yet,

This will build all the way till news then explode , imo

Time to buy,

https://www.defenseworld.net/2025/01/26/immupharma-lonimm-shares-up-15-6-time-to-buy.html#google_vignette

Someone mentioned yesterday about some warrants than can now to cash in because the price finished above 4p,

Is this correct

Try to find information on the warrants which have been mentioned,

Or can someone just explain what’s happening,

Thanks in advance

The advances made by ImmuPharma with the P140 program, particularly in the latter part of 2024, have led to significant interest from leading Biopharmaceutical companies and we are progressing discussions as we move to establish global licensing agreements.

There have been eleven $1bn+ licensing deals for immunology assets across the BioPharma industry from 2023 to late September 2024. The current trend suggests that Immunology and Autoimmune drug assets are becoming very highly sought by the leading BioPharma companies.

Closed at 405p

Have a good weekend

4p or above get those warrant done

Has trading stoped , lol

Sorry I missed that, that’s great news then, may get an RNs Monday

I might be wrong but normally it’s high so they are in profit, and can sell above the 4p mark,

If it is an iceberg order an it large , they might increase the buys to clear before close,

Interesting thanks

So that’s what’s holding this back, large orders

You learn something every day.

https://www.investopedia.com/terms/i/icebergorder.asp

Need to get to 6 or 7p before they will take the warrents

Holding strong, big push into close, let’s get to 4,5p

Ey highlights:

· The Company entered into a Warrant Instrument ("Warrant Instrument") with Incanthera on 26 February 2020, whereby Incanthera created and issued Warrants to ImmuPharma to subscribe in cash at 9.5p per share, for 7,272,740 Ordinary Shares, valid until 6 September 2023. On 18 August 2023 Incanthera agreed with the Company to extend the Warrant Instrument by 12 months to 6 September 2024.

· Incanthera has now agreed with the Company to extend the Warrant Instrument to 31 March 2025.

· A cash consideration of £75,000 ("Consideration") has been paid by ImmuPharma to obtain the extension.

· Other than the change in the expiry period, all other provisions in the Warrant Instrument remain the same.

ImmuPharma currently owns no shares in Incanthera, having sold its previous holding of c9.9 million shares, as notified on 3 June 2024, at a price of 15p, realising proceeds of c.£1.5 million for the Company.

Tim McCarthy, ImmuPharma's Chairman & CEO, is also the Chairman of Incanthera and has a holding of 3,931,646 shares in Incanthera (3.36% of Incanthera's issued share capital).